FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 330:1841-1845 June 30, 1994 Number 26 Next

	Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background There has been no new effective drug therapy for patients with severe ulcerative colitis since corticosteroids were introduced almost 40 years ago. In an uncontrolled study, 80 percent of 32 patients with active ulcerative colitis refractory to corticosteroid therapy had a response to cyclosporine therapy.

Methods We conducted a randomized, double-blind, controlled trial in which cyclosporine (4 mg per kilogram of body weight per day) or placebo was administered by continuous intravenous infusion to 20 patients with severe ulcerative colitis whose condition had not improved after at least seven days of intravenous corticosteroid therapy. A response to therapy was defined as an improvement in a numerical symptom score (0 indicated no symptoms, and 21 severe symptoms) leading to discharge from the hospital and treatment with oral medications. Failure to respond to therapy resulted in colectomy, but some patients in the placebo group who had no response and no urgent need for surgery were subsequently treated with cyclosporine.

Results Nine of 11 patients (82 percent) treated with cyclosporine had a response within a mean of seven days, as compared with 0 of 9 patients who received placebo (P<0.001). The mean clinical-activity score fell from 13 to 6 in the cyclosporine group, as compared with a decrease from 14 to 13 in the placebo group. All five patients in the placebo group who later received cyclosporine therapy had a response.

Conclusions Intravenous cyclosporine therapy is rapidly effective for patients with severe corticosteroid-resistant ulcerative colitis.

Source Information

From the Department of Medicine, Division of Gastroenterology (S.L., D.H.P., A.K.), and the Department of Surgery (I.G., J.B.), Mt. Sinai School of Medicine, New York; and the Department of Medicine, Division of Gastroenterology (G.G., S.H.), and the Department of Surgery (F.M.), University of Chicago Medical Center, Chicago.

Address reprint requests to Dr. Lichtiger at 1185 Park Ave., New York, NY 10128.

Full Text of this Article

Related Letters:

Lithium in the Treatment of Mood Disorders
Stern R., Price L. H., Heninger G. R.
Extract | Full Text  
N Engl J Med 1995; 332:127-128, Jan 12, 1995. Correspondence

This article has been cited by other articles:

• Hommel, K. A., Baldassano, R. N. (2009). Brief Report: Barriers to Treatment Adherence in Pediatric Inflammatory Bowel Disease. J Pediatr Psychol 0: jsp126v1-jsp126 [Abstract] [Full Text]  
• Ingerski, L. M, Baldassano, R. N, Denson, L. A, Hommel, K. A (2009). Barriers to Oral Medication Adherence for Adolescents with Inflammatory Bowel Disease. J Pediatr Psychol 0: jsp085v1-jsp085 [Abstract] [Full Text]  
• Satoh, Y., Ishiguro, Y., Sakuraba, H., Kawaguchi, S., Hiraga, H., Fukuda, S., Nakane, A. (2009). Cyclosporine regulates intestinal epithelial apoptosis via TGF-{beta}-related signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 297: G514-G519 [Abstract] [Full Text]  
• Festen, E A M, Goyette, P, Scott, R, Annese, V, Zhernakova, A, Lian, J, Lefebvre, C, Brant, S R, Cho, J H, Silverberg, M S, Taylor, K D, de Jong, D J, Stokkers, P C, Mcgovern, D, Palmieri, O, Achkar, J-P, Xavier, R J, Daly, M J, Duerr, R H, Wijmenga, C, Weersma, R K, Rioux, J D (2009). Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 58: 799-804 [Abstract] [Full Text]  
• Garud, S., Peppercorn, M. A. (2009). Review: Ulcerative colitis: current treatment strategies and future prospects. Therapeutic Advances in Gastroenterology 2: 99-108 [Abstract]  
• Hommel, K. A., Davis, C. M., Baldassano, R. N. (2008). Medication Adherence and Quality of Life in Pediatric Inflammatory Bowel Disease. J Pediatr Psychol 33: 867-874 [Abstract] [Full Text]  
• van den Broek, F J C, Fockens, P, van Eeden, S, Reitsma, J B, Hardwick, J C H, Stokkers, P C F, Dekker, E (2008). Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions. Gut 57: 1083-1089 [Abstract] [Full Text]  
• Stremmel, W., Ehehalt, R., Autschbach, F., Karner, M. (2007). Phosphatidylcholine for Steroid-Refractory Chronic Ulcerative Colitis: A Randomized Trial. ANN INTERN MED 147: 603-610 [Abstract] [Full Text]  
• Leenen, C. H. M., Dieleman, L. A. (2007). Inulin and Oligofructose in Chronic Inflammatory Bowel Disease. J. Nutr. 137: 2572S-2575S [Abstract] [Full Text]  
• Van Assche, G, Sandborn, W J, Feagan, B G, Salzberg, B A, Silvers, D, Monroe, P S, Pandak, W M, Anderson, F H, Valentine, J F, Wild, G E, Geenen, D J, Sprague, R, Targan, S R, Rutgeerts, P, Vexler, V, Young, D, Shames, R S (2006). Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 55: 1568-1574 [Abstract] [Full Text]  
• Herrlinger, K R, Fellermann, K, Stange, E F (2006). Tacrolimus--finally!. Gut 55: 1224-1225 [Full Text]  
• Ogata, H, Matsui, T, Nakamura, M, Iida, M, Takazoe, M, Suzuki, Y, Hibi, T (2006). A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 55: 1255-1262 [Abstract] [Full Text]  
• Jakobovits, S. L., Travis, S. P. L. (2006). Management of acute severe colitis. Br Med Bull 75-76: 131-144 [Abstract] [Full Text]  
• Sands, B E (2006). Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?. Gut 55: 437-441 [Abstract] [Full Text]  
• Lakatos, L, Lakatos, P L (2006). Management of inflammatory bowel diseases in Eastern Europe.. Postgrad. Med. J. 82: 270-273 [Abstract] [Full Text]  
• Ardizzone, S, Maconi, G, Russo, A, Imbesi, V, Colombo, E, Bianchi Porro, G (2006). Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55: 47-53 [Abstract] [Full Text]  
• Pham, C. Q., Efros, C. B, Berardi, R. R (2006). Cyclosporine for Severe Ulcerative Colitis. The Annals of Pharmacotherapy 40: 96-101 [Abstract] [Full Text]  
• Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., de Villiers, W. J.S., Present, D., Sands, B. E., Colombel, J. F. (2005). Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. NEJM 353: 2462-2476 [Abstract] [Full Text]  
• Sato, T, Nakai, T, Tamura, N, Okamoto, S, Matsuoka, K, Sakuraba, A, Fukushima, T, Uede, T, Hibi, T (2005). Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut 54: 1254-1262 [Abstract] [Full Text]  
• Gironella, M, Iovanna, J L, Sans, M, Gil, F, Penalva, M, Closa, D, Miquel, R, Pique, J M, Panes, J (2005). Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease. Gut 54: 1244-1253 [Abstract] [Full Text]  
• Waters, V., Sokol, S., Reddy, B., Soong, G., Chun, J., Prince, A. (2005). The Effect of Cyclosporin A on Airway Cell Proinflammatory Signaling and Pneumonia. Am. J. Respir. Cell Mol. Bio. 33: 138-144 [Abstract] [Full Text]  
• Cima, R. R., Pemberton, J. H. (2005). Medical and Surgical Management of Chronic Ulcerative Colitis. Arch Surg 140: 300-310 [Full Text]  
• Bennink, R. J., Peeters, M., Rutgeerts, P., Mortelmans, L. (2004). Evaluation of Early Treatment Response and Predicting the Need for Colectomy in Active Ulcerative Colitis with 99mTc-HMPAO White Blood Cell Scintigraphy. JNM 45: 1698-1704 [Abstract] [Full Text]  
• Carter, M J, Lobo, A J, Travis, S P L (2004). Guidelines for the management of inflammatory bowel disease in adults. Gut 53: v1-v16 [Full Text]  
• Kamm, M A (2004). Early surgical intervention in ulcerative colitis. Gut 53: 308-309 [Full Text]  
• Probert, C S J, Hearing, S D, Schreiber, S, Kuhbacher, T, Ghosh, S, Arnott, I D R, Forbes, A (2003). Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52: 998-1002 [Abstract] [Full Text]  
• (2003). Inducing remission in inflammatory bowel disease. DTB 41: 30-32 [Abstract] [Full Text]  
• Loftus, C G, Loftus, E V Jr, Sandborn, W J (2003). Cyclosporin for refractory ulcerative colitis. Gut 52: 172-173 [Full Text]  
• Rafiee, P., Johnson, C. P., Li, M. S., Ogawa, H., Heidemann, J., Fisher, P. J., Lamirand, T. H., Otterson, M. F., Wilson, K. T., Binion, D. G. (2002). Cyclosporine A Enhances Leukocyte Binding by Human Intestinal Microvascular Endothelial Cells through Inhibition of p38 MAPK and iNOS. PARADOXICAL PROINFLAMMATORY EFFECT ON THE MICROVASCULAR ENDOTHELIUM. J. Biol. Chem. 277: 35605-35615 [Abstract] [Full Text]  
• Podolsky, D. K. (2002). Inflammatory Bowel Disease. NEJM 347: 417-429 [Full Text]  
• Cuffari, C, Hunt, S, Bayless, T (2001). Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 48: 642-646 [Abstract] [Full Text]  
• Yeung, M M-W, Melgar, S, Baranov, V, Oberg, A, Danielsson, A, Hammarstrom, S, Hammarstrom, M-L (2000). Characterisation of mucosal lymphoid aggregates in ulcerative colitis: immune cell phenotype and TcR-gamma delta expression. Gut 47: 215-227 [Abstract] [Full Text]  
• Ghosh, S., Shand, A., Ferguson, A. (2000). Regular review: Ulcerative colitis. BMJ 320: 1119-1123 [Full Text]  
• Kerr, S. W., Wolyniec, W. W., Filipovic, Z., Nodop, S. G., Braza, F., Winquist, R. J., Noonan, T. C. (1999). Repeated Measurement of Intestinal Permeability as an Assessment of Colitis Severity in HLA-B27 Transgenic Rats. J. Pharmacol. Exp. Ther. 291: 903-910 [Abstract] [Full Text]  
• CORRIGAN, C J (1999). Glucocorticoid unresponsiveness in severe ulcerative colitis. Gut 45: 324-325 [Full Text]  
• Hearing, S D, Norman, M, Probert, C S J, Haslam, N, Dayan, C M (1999). Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 45: 382-388 [Abstract] [Full Text]  
• Aiko, S., Conner, E. M., Fuseler, J. A., Grisham, M. B. (1997). Effects of Cyclosporine or FK506 in Chronic Colitis. J. Pharmacol. Exp. Ther. 280: 1075-1084 [Abstract] [Full Text]  
• Hanauer, S. B. (1996). Inflammatory Bowel Disease. NEJM 334: 841-848 [Full Text]  
• Forgacs, I. (1995). Recent Advances: Clinical gastroenterology. BMJ 310: 113-116 [Full Text]  
• Vincent, F., Bensousan, T.-A., Whitmore, S. E., Lichtiger, S. (1995). Cyclosporine in Severe Ulcerative Colitis. NEJM 332: 127-127 [Full Text]  
• (1994). Cyclosporine for Inflammatory Bowel Disease: Mixed Results. Journal Watch Dermatology 1994: 19-19 [Full Text]  
• (1994). CYCLOSPORINE FOR INFLAMMATORY BOWEL DISEASE. JWatch General 1994: 2-2 [Full Text]  
• Sartor, R. B. (1994). Cyclosporine Therapy for Inflammatory Bowel Disease. NEJM 330: 1897-1898 [Full Text]